Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Baniel

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
British Journal of Cancer|August 17, 2000
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in IsraelA Vazina, J Baniel, Y Yaacobi, et al.
The Journal of Urology|February 1, 1996
Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumorsP Albers, T M Ulbright, J Albers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2020
Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screeningN Segal, Y Ber, O Benjaminov, et al.
European Urology|June 9, 2004
Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladderA G van der Heijden, L A Kiemeney, O N Gofrit, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
British Journal of Cancer|August 17, 2000
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in IsraelA Vazina, J Baniel, Y Yaacobi, et al.
The Journal of Urology|February 1, 1996
Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumorsP Albers, T M Ulbright, J Albers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2020
Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screeningN Segal, Y Ber, O Benjaminov, et al.
European Urology|June 9, 2004
Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladderA G van der Heijden, L A Kiemeney, O N Gofrit, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
Pageof 8